Buy Cjc 1295 Dac

Q: Is CJC-1295 DAC approved for human consumption or therapeutic use?

No. CJC-1295 DAC supplied by PX1 Research is strictly intended for laboratory research use only (in vitro and preclinical animal research). It is not approved for human consumption, therapeutic use, or clinical administration.

Q: How can institutional laboratories set up bulk or wholesale purchasing?

Research institutions and qualified laboratories can apply for a wholesale account through the PX1 Research wholesale portal to access bulk pricing, lot reservation, and dedicated account support.

When evaluating where to buy CJC 1295 DAC for laboratory investigation, research institutions require precise analytical verification, batch-level purity documentation, and verified biochemical stability. CJC-1295 with Drug Affinity Complex (DAC) is a long-acting synthetic growth hormone-releasing hormone (GHRH) analog engineered to sustain elevated growth hormone (GH) and insulin-like growth factor 1 (IGF-1) expression in preclinical research models.

GMP-compliant U.S. facilities

ISO 17025 third-party COAs

100% domestic — no imports

Fast tracked domestic shipping

Shop research peptides

Quick answer

Reviewed by PX1 Research scientific team

Key takeaways

[CJC-1295](/research-peptides/cjc-1295-no-dac) DAC is a modified 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH 1-29).
The primary mechanism of [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC involves selective activation of the growth hormone-releasing hormone receptor (GHRHR) located on anterior pituitary somatotrophs.
The defining feature of [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC is the bioconjugate linker appended to the 29th amino acid residue.
In preclinical model systems, elevated IGF-1 resulting from [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC administration is studied for its downstream effects on cellular repair and metabolic regulation.

Overview of CJC-1295 DAC in Preclinical Research

CJC-1295 DAC is a modified 29-amino acid peptide derivative of growth hormone-releasing hormone (GHRH 1-29). In laboratory settings, GHRH peptides are studied for their capacity to bind to specific pituitary receptors and stimulate the endogenous synthesis and secretion of growth hormone. Standard native GHRH exhibits a short biological half-life due to rapid enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) in blood serum.

To address this rapid clearance in experimental setups, bioconjugate chemistry was applied to modify the peptide chain. The inclusion of a Drug Affinity Complex (DAC)—specifically a reactive maleimido derivative attached via a lysine linker at the C-terminus—allows the molecule to form a stable covalent bond with endogenous serum albumin following administration in test models. Investigators who seek to buy CJC 1295 DAC typically focus on how this structural alteration affects hormone signaling dynamics over multi-day observation windows.

Through this bioconjugation process, CJC-1295 DAC exhibits significantly altered pharmacokinetics compared to unmodified GHRH fragments. Preclinical literature demonstrates that the covalent bioconjugation prevents cleavage by circulating peptidases, transforming a short-acting signaling molecule into a long-lasting reagent for studying sustained GH axis activation.

Biochemical Mechanism and Receptor Affinity

The primary mechanism of CJC-1295 DAC involves selective activation of the growth hormone-releasing hormone receptor (GHRHR) located on anterior pituitary somatotrophs. Upon receptor engagement, the peptide activates a G-protein-coupled receptor pathway, initiating adenylate cyclase activity and elevating intracellular cyclic adenosine monophosphate (cAMP). This second-messenger cascade signals the transcription and exocytosis of growth hormone.

In contrast to secretagogues that act on the ghrelin receptor (GHSR-1a), CJC-1295 DAC acts exclusively through the canonical GHRH signaling pathway. In vitro assays demonstrate that GHRHR binding triggers physiological GH release without inducing hypercortisolemia or excessive prolactin secretion. Researchers investigating pituitary response kinetics frequently review our comprehensive index of growth hormone secretagogues to compare pathway specificity.

Because of the continuous receptor engagement permitted by the albumin-bound complex, animal studies show a sustained elevation in basal GH concentrations rather than isolated, sharp spikes. This sustained signal drives downstream hepatic production of insulin-like growth factor 1 (IGF-1), enabling long-term research into cellular differentiation, protein synthesis, and tissue remodeling mechanisms.

Structural Mechanics of the Drug Affinity Complex (DAC)

The defining feature of CJC-1295 DAC is the bioconjugate linker appended to the 29th amino acid residue. The chemical name for the modified construct is D-Ala2, Gln8, Ala15, Leu27-GHRH(1-29)-Lys(Maleimidopropionyl)-NH2. The inclusion of D-alanine at position 2 yields primary resistance against DPP-IV enzymatic cleavage, while the maleimidopropionyl group provides functional bioconjugation capacity.

When introduced into serum-containing media or live animal models, the maleimido group reacts specifically with the free thiol group on Cys34 of serum albumin. Albumin acts as an endogenous carrier macromolecule, protecting the small peptide from renal clearance and enzymatic degradation while retaining the active motif's availability to interact with GHRHR.

Data derived from preclinical pharmacokinetics demonstrate that while native GHRH fragments possess a plasma half-life of minutes, CJC-1295 DAC maintains biological activity for several days in mammalian models. Laboratories interested in exploring long-acting peptides across broader signal cascades can reference our broader research library for comparative molecular structures.

Preclinical Applications in Tissue Repair and Cellular Metabolism

In preclinical model systems, elevated IGF-1 resulting from CJC-1295 DAC administration is studied for its downstream effects on cellular repair and metabolic regulation. Animal models of musculoskeletal injury demonstrate that sustained GHRH signaling accelerates satellite cell proliferation, myoblast differentiation, and collagen deposition within connective tissues.

Research in rodent models of metabolic stress indicates that chronic GHRH pathway activation influences lipolysis and nitrogen retention. In vitro cellular cultures exposed to serum from CJC-1295 DAC-treated animal models demonstrate upregulation of protein translation machinery via the Akt/mTOR signaling axis, providing a controlled system to analyze muscle tissue conservation under catabolic stress.

Furthermore, preclinical research indicates potential applications in bone density models, osteoblast activity assays, and cardiac tissue remodeling after ischemia. By maintaining steady downstream IGF-1 expression without requiring frequent re-administration in experimental protocols, CJC-1295 DAC provides a stable environment for long-term physiological monitoring.

Comparative Analysis: CJC-1295 DAC vs. Related Peptide Constructs

Understanding the comparative attributes of GHRH analogs and growth hormone secretagogues is critical when designing experimental protocols. Researchers frequently compare CJC-1295 DAC with CJC-1295 No DAC, Sermorelin, and Ipamorelin to evaluate differences in half-life, pulse generation, and receptor selectivity.

While CJC-1295 DAC forms a permanent covalent bond with serum albumin to provide multi-day signaling, CJC-1295 No DAC (also known as Mod GRF 1-29) lacks the maleimido linker. Consequently, CJC-1295 No DAC exhibits a significantly shorter half-life (30–60 minutes in animal models) and produces acute, transient spikes in GH rather than elevated baseline concentrations.

Similarly, Sermorelin represents the unmodified 1-29 amino acid chain of human GHRH, exhibiting rapid clearance and requiring precise timing in acute secretion studies. On the other hand, selective ghrelin receptor agonists like Ipamorelin trigger GH release through an entirely distinct receptor pathway (GHSR-1a). Dual-pathway research models often evaluate combinations of GHRH analogs and GHSR agonists to examine synergistic somatotroph stimulation. Explore our complete selection of research peptides for complementary reagents.

Quality Verification: HPLC, Mass Spectrometry, and Endotoxin Standards

When purchasing peptides for laboratory experimentation, batch purity and consistency are vital parameters to ensure reproducible results. Minor impurities, truncated peptide sequences, or residual organic solvents can compromise cell viability, interfere with binding assays, and invalidate experimental data.

At PX1 Research, every lot of CJC-1295 DAC undergoes rigorous verification through an independent ISO 17025 accredited laboratory. Quality testing utilizes High-Performance Liquid Chromatography (RP-HPLC) to verify chemical purity standards exceeding 98.0%, combined with Mass Spectrometry (MS) to confirm precise molecular weight and sequence identity.

Furthermore, because bacterial endotoxins (lipopolysaccharides) can trigger non-specific inflammatory responses in cell cultures and animal models, PX1 Research subjects all lyophilized lots to chromogenic LAL endotoxin testing. Every product is backed by a lot-specific Certificate of Analysis (COA) detailing HPLC chromatograms, mass spectra, and endotoxin assay results, ensuring institutional compliance and uncompromised research integrity.

Laboratory Reconstitution and Handling Protocols

Lyophilized CJC-1295 DAC must be reconstituted properly under sterile laboratory conditions prior to use in assays or animal administration models. To maintain peptide integrity and prevent premature cleavage, researchers should follow established laboratory protocols available in our peptide reconstitution guide.

Reconstitution should be conducted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline, depending on the requirements of the downstream assay. The diluent should be introduced gently along the glass vial wall rather than sprayed directly onto the lyophilized cake. Gentle swirl agitation is recommended; vigorous shaking or vortexing must be avoided, as mechanical shear forces can cause peptide denaturation or aggregation.

Once fully dissolved, the solution should be inspected visually for clarity. Reconstituted peptide solutions should be aliquoted into single-use polypropylene tubes to minimize repeat freeze-thaw cycles, which degrade peptide bonds over time.

Storage Conditions and Stability Guidelines

Lyophilized CJC-1295 DAC powder exhibits high thermal stability when stored under controlled conditions. For long-term preservation, sealed vials should be kept at -20°C or -80°C in a dry environment protected from direct light exposure. Under sub-zero storage conditions, un-reconstituted lyophilized cakes remain stable for up to 24 months.

Following reconstitution, liquid solutions are significantly more susceptible to hydrolytic cleavage and oxidation. Reconstituted CJC-1295 DAC stored at 2°C to 8°C (refrigerated) should be utilized within 21 to 28 days to prevent loss of biological activity.

If experimental protocols require long-term storage of reconstituted solutions, aliquots should be frozen rapidly at -80°C. Researchers should ensure that freeze-thaw cycles are strictly limited, as repeated phase transitions accelerate peptide degradation.

Procuring CJC-1295 DAC for Institutional Research

PX1 Research is a dedicated USA-based supplier of high-purity research compounds engineered specifically for laboratory and analytical use. We serve university laboratories, private biotechnology firms, and institutional research facilities requiring uncompromising quality standards, lot traceability, and batch reliability.

All products are synthesized in state-of-the-art GMP-compliant facilities within the United States, shipped directly from our primary distribution hubs in California and Arizona. Orders placed Monday through Friday ship same-day to minimize supply chain delays for active research projects.

For high-volume requirements or multi-center research grants, laboratories can access tiered procurement pricing and dedicated account support through our wholesale program. All compounds sold by PX1 Research are strictly designated for in vitro, analytical, and preclinical research use only.

Frequently Asked Questions

What is the primary structural difference between CJC-1295 DAC and CJC-1295 No DAC?

CJC-1295 DAC includes a Drug Affinity Complex (a maleimido derivative attached via a lysine linker) at its C-terminus. This group enables covalent binding to circulating serum albumin in animal models, extending its half-life to several days. CJC-1295 No DAC lacks this linker, resulting in a much shorter plasma half-life of 30 to 60 minutes.

How does PX1 Research verify the purity of CJC-1295 DAC?

Every lot of CJC-1295 DAC is tested by an independent ISO 17025 accredited laboratory using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to confirm >98% purity, Mass Spectrometry (MS) to verify molecular weight, and LAL assays to ensure low endotoxin levels.

What solvent is recommended for reconstituting CJC-1295 DAC in a lab setting?

Reconstitution is typically performed using sterile Bacteriostatic Water (containing 0.9% benzyl alcohol) or sterile 0.9% sodium chloride solution, depending on the requirements of the preclinical assay or cellular model.

What is the expected biological half-life of CJC-1295 DAC in animal models?

In preclinical mammalian models, the albumin-bound CJC-1295 DAC complex exhibits an extended elimination half-life ranging from 6 to 8 days, maintaining sustained elevated serum GH and IGF-1 levels.

How should lyophilized CJC-1295 DAC be stored prior to reconstitution?

Unopened lyophilized vials should be stored at -20°C to -80°C in a dry environment away from light, where they remain biochemically stable for up to 24 months.

What endotoxin threshold is maintained for PX1 Research peptides?

PX1 Research verifies that endotoxin levels remain strictly below standard experimental thresholds (<0.1 EU/mg) to prevent non-specific immune activation or cell toxicity in sensitive research assays.

Is CJC-1295 DAC approved for human consumption or therapeutic use?